Skip to content

Cerebral Metabolic Changes Associated With Thalamic Stimulation

Cerebral Metabolic Changes Associated With Thalamic Stimulation

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01141764
Enrollment
4
Registered
2010-06-10
Start date
2010-03-31
Completion date
2014-02-28
Last updated
2014-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

pediatrics, Epilepsy, Deep Brain Stimulation, Positron Emission Tomography

Brief summary

The purpose of this research study is to evaluate the brain circuits function and circuits involved in the mechanism of thalamic DBS in patients with medically refractory epilepsy.

Detailed description

Deep brain stimulation (DBS) of the anterior nucleus of the thalamus in patients with medically refractory epilepsy has been shown to be efficacious. Studies have estimated a 46-76% reduction in seizures relative to the baseline. However, the exact anatomic circuitry involved in the mechanism of DBS in epilepsy remains unknown. Positron emission tomography (PET) studies can provide clues to the metabolic activity associated with DBS activation. In our study, patients will be scanned with their DBS electrodes turned on and off. PET data captured during these two distinct states may show characteristic differences in cerebral glucose metabolism and modulatory effects of surrounding cerebral structures, thus providing clues to how DBS works to prevent seizures.

Interventions

The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner. This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days.

PROCEDUREMagnetic Resonance Imaging (MRI)

MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.

OTHERNeuropsychological Testing

On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on.

Sponsors

University Health Network, Toronto
CollaboratorOTHER
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* 18-85 years old * currently have DBS implanted for medically refractory epilepsy * Women of childbearing age will be required to use established contraceptive methods while enrolled in the study.

Exclusion criteria

Patients who: * are \< 18 years of age or \> 85 years of age * are medically unstable * are women who are potentially pregnant, pregnant or nursing * have had PET imaging within 1 year.

Design outcomes

Primary

MeasureTime frameDescription
Areas of the brain with low activitywithin 30 days of enrollment in the studyThis measure will be based on the results of two PET scans done on separate days. The stimulator will be on during the first PET image acquisition and off during the second PET image acquisition.

Secondary

MeasureTime frameDescription
Brain Abnormalitieswithin 30 days of enrollment in the studyOne Magnetic Resonance Imaging (MRI) scan will be used to take detailed images of the brain and detect whether there are any abnormalities.
Ability to learn and understandwithin 30 days of enrollment in the studyOne session of neuropsychological testing will be done in order to assess the subject's ability to learn and understand.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026